HT-101

DRUG3 trials

Sponsors

Suzhou HepaThera Biotech Co., Ltd.

Conditions

Chronic Hepatitis B

Phase 1

This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

CompletedNCT06746311

Suzhou HepaThera Biotech Co., Ltd.Chronic Hepatitis B

Start: 2022-11-22End: 2024-06-17Updated: 2024-12-24

A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, not recruitingNCT07183306

Suzhou HepaThera Biotech Co., Ltd.Chronic Hepatitis B

Start: 2024-12-30End: 2027-05-03Updated: 2025-09-19

Phase 2

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, not recruitingNCT07245953

Suzhou HepaThera Biotech Co., Ltd.Chronic Hepatitis B

Start: 2025-11-05End: 2027-05-31Target: 60Updated: 2025-11-24